Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumithra J Mandrekar

Showing results (111-120 of 157) with videos related to

Pageof 16
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2012
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG studyThanyanan Reungwetwattana, Julian R Molina, Sumithra J Mandrekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2022
Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment StudiesJoseph M Unger, Michael LeBlanc, Suzanne George, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 13, 2012
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528Grace K Dy, Sumithra J Mandrekar, Garth D Nelson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2007
Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancerJann N Sarkaria, Paul Schwingler, Steven E Schild, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancerCynthia X Ma, Suresh Nair, Sachdev Thomas, et al.
Investigational New Drugs|October 12, 2013
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabineMatthew P Goetz, Heidi A McKean, Joel M Reid, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 30, 2011
Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III studyHiran C Fernando, Rodney J Landreneau, Sumithra J Mandrekar, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 5, 2011
The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trialHiran C Fernando, Rodney J Landreneau, Sumithra J Mandrekar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 StudyErin L Schenk, Sumithra J Mandrekar, Grace K Dy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancerHiran C Fernando, Rodney J Landreneau, Sumithra J Mandrekar, et al.
Pageof 16

Showing results (111-120 of 157) with videos related to

Sort By:
Pageof 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2012
Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG studyThanyanan Reungwetwattana, Julian R Molina, Sumithra J Mandrekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2022
Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment StudiesJoseph M Unger, Michael LeBlanc, Suzanne George, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 13, 2012
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528Grace K Dy, Sumithra J Mandrekar, Garth D Nelson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 1, 2007
Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancerJann N Sarkaria, Paul Schwingler, Steven E Schild, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancerCynthia X Ma, Suresh Nair, Sachdev Thomas, et al.
Investigational New Drugs|October 12, 2013
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabineMatthew P Goetz, Heidi A McKean, Joel M Reid, et al.
The Journal of Thoracic and Cardiovascular Surgery|August 30, 2011
Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III studyHiran C Fernando, Rodney J Landreneau, Sumithra J Mandrekar, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 5, 2011
The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trialHiran C Fernando, Rodney J Landreneau, Sumithra J Mandrekar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 StudyErin L Schenk, Sumithra J Mandrekar, Grace K Dy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancerHiran C Fernando, Rodney J Landreneau, Sumithra J Mandrekar, et al.
Pageof 16